XP23829
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for XP23829, covering 2022-04-12 to 2022-04-12. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis [Phase 2]